Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases

Clicks: 259
ID: 267625
2019
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
In a post-hoc analysis of data from phase 3 clinical trials, vedolizumab significantly improved patient-reported symptoms of UC and CD as early as week 2 of treatment, continuing through the first 6 weeks-especially when given as first-line biologic therapy. ClinicalTrials.gov no: NCT00783718, NCT00 …
Reference Key
bg2019clinicalrapid Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Feagan BG;Lasch K;Lissoos T;Cao C;Wojtowicz AM;Khalid JM;Colombel JF;;
Journal clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association
Year 2019
DOI
DOI not found
URL
https://www.pubmed.gov/29857145/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male adolescent aged middle aged young adult randomized controlled trials as topic 80 and over Antibodies Monoclonal Brian G Feagan time factors patient reported outcome measures placebos / administration & dosage jean-frédéric colombel karen lasch clinical trials phase iii as topic pmid:29857145 doi:10.1016/j.cgh.2018.05.026 humanized / administration & dosage* gastrointestinal agents / administration & dosage* inflammatory bowel diseases / drug therapy* inflammatory bowel diseases / pathology*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.